Previous 10 | Next 10 |
Gainers: Protagenic Therapeutics (PTIX) +67%.Obalon Therapeutics (OBLN) +57%.Precipio (PRPO) +35%.Cue Biopharma (CUE) +31%.SemiLEDs (LEDS) +28%.CKX Lands (CKX) +27%.Tecnoglass (TGLS) +24%.Soliton (SOLY) +24%.Party City Holdco (PRTY) +19%.uCloudlink (UCL) +16%.Losers: Rekor...
Soligenix (SNGX) is trading sharply lower after the company announced its decision not to pursue a rolling submission for its marketing application of HyBryte (SGX301) in the treatment of cutaneous T-cell lymphoma ((CTCL)).After discussions with the FDA, “the company decided ...
Gainers: Protagenic Therapeutics (PTIX) +44%, Cue Biopharma CUE +36%, Obalon Therapeutics (OBLN) +28%, Soliton SOLY +24%, Precipio (PRPO) +20%.Losers: Insmed INSM -17%, Soligenix (SNGX) -17%, Kodiak Sciences (KOD) -14%, Dynavax ...
Soligenix (SNGX) -22% as company now plans to submit the NDA in the 1H22.LM Funding America (LMFA) -11%.Senmiao Technology (AIHS) -7%.InnSuites Hospitality (IHT) -5%.Ra Medical Systems (RMED) -6%.Galapagos (GLPG) -5%.Stealth BioTherapeutics (MITO) -5%.Luokung Technology (LKCO) -5%. For...
HyBryte™ Awarded Innovation Passport in the United Kingdom PR Newswire PRINCETON, N.J. , May 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializin...
Broad Efficacy and Improved Safety Profile of HyBryte™ Presented at Society for Investigative Dermatology Virtual Meeting PR Newswire PRINCETON, N.J. , May 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage...
Soligenix Presents at the National Foundation for Infectious Diseases Annual Conference on Vaccinology Research COVID-19 Vaccine Program Demonstrates Immunogenicity In Non-Human Primates PR Newswire PRINCETON, N.J. , April 28, 2021 /PRNewswire/ -- Solige...
HyBryte™ Expanded Efficacy and Safety Data Presented at the American Academy of Dermatology Meeting PR Newswire PRINCETON, N.J. , April 26, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical compa...
Soligenix Announces Presentations at Prominent Scientific Conferences Key Data Outcomes Presented for HyBryte™ and CiVax™ PR Newswire PRINCETON, N.J. , April 13, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company)...
Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCL PR Newswire PRINCETON, N.J. , April 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical comp...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's ( Nasdaq:SNGX ) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte...